Compare ADMA Biologics Inc (ADMA) vs Ford Motor Company (F) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Ford Motor Company — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Ford Motor Company trades at $13.85 (market cap $55.75B). The key difference: Ford Motor Company is far larger — about 25.1× ADMA Biologics Inc's market cap, and Ford Motor Company pays a 4.29% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | F | |
|---|---|---|
Market Cap | $2.22B | $55.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $17.44 |
52-Week Low | $7.60 | $11.21 |
Enterprise Value | $2.29B | $187.71B |
Dividend Yield | — | 4.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Ford (F) trades at $13.86, down 1.14%, with a bearish technical signal. Recent earnings show volatility, with Q1 and Q2 2026 beats but a Q4 2025 miss. The company reported a net loss of $8.18B for 2025, though operating cash flow remains strong at $21.28B. News highlights the upcoming affordable Fathom EV truck priced at $28,350, targeting market share gains amid high vehicle prices.
The outlook is mixed: analyst consensus is a Buy with a $16.18 target, offering potential upside, but risks include intense EV competition, profitability challenges, and high debt levels. The stock's low P/E of 11.84 may attract value investors, but execution on new models is critical for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
